{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:05:03Z","timestamp":1791032703170,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1007\/s11897-004-0005-8","type":"journal-article","created":{"date-parts":[[2007,8,19]],"date-time":"2007-08-19T10:58:38Z","timestamp":1187521118000},"page":"171-175","source":"Crossref","is-referenced-by-count":12,"title":["Aldosterone in heart failure: Pathophysiology and treatment"],"prefix":"10.1007","volume":"1","author":[{"given":"Allan D.","family":"Struthers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"5_CR1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","volume":"31","author":"R Rocha","year":"1998","unstructured":"Rocha R, Chander PN, Khanna K, et al.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451\u2013458. This is the first demonstration that aldosterone blockade produces tissue injury protection (in experimental animals).","journal-title":"Hypertension"},{"key":"5_CR2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cvr\/26.7.671","volume":"26","author":"CG Brilla","year":"1992","unstructured":"Brilla CG, Weber KT: Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992, 26:671\u2013677. This is the first demonstration that aldosterone promotes myocardial fibrosis in experimental animals.","journal-title":"Cardiovasc Res"},{"key":"5_CR3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594\u2013597. This is the first demonstration in humans that aldosterone blockade improved endothelial function and vascular NO.","journal-title":"Circulation"},{"key":"5_CR4","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","volume":"76","author":"CS Barr","year":"1995","unstructured":"Barr CS, Lang CC, Hanson J, et al.: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995, 76:1259\u20131265. This is the first demonstration that adding spironolactone to an ACE inhibitor in heart failure had novel beneficial effects (on sympathetic activity and arrhythmias).","journal-title":"Am J Cardiol"},{"key":"5_CR5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","volume":"35","author":"RJ MacFadyen","year":"1997","unstructured":"MacFadyen RJ, Barr CS, Struthers AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997, 35:30\u201334. This is the first demonstration in humans that aldosterone blockade reduces collagen markers in the bloodstream.","journal-title":"Cardiovasc Res"},{"key":"5_CR6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709\u2013717. This is the landmark RALES trial that proved that adding spironolactone reduced mortality in heart failure.","journal-title":"N Engl J Med"},{"key":"5_CR7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321. This is the landmark EPHESUS trial that showed that eplerenone reduced total mortality in post-myocardial infarction left ventricular dysfunction.","journal-title":"N Engl J Med"},{"key":"5_CR8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709\u2013716. This is the first demonstration that eplerenone had antihypertensive activity.","journal-title":"Am J Hypertens"},{"key":"5_CR9","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy Study. Circulation 2003, 108:1831\u20131838. This 4E study showed that eplerenone reduces left ventricular mass in left ventricular hypertrophy (on its own and with an ACE inhibitor).","journal-title":"Circulation"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-004-0005-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-004-0005-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-004-0005-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:09:45Z","timestamp":1559434185000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-004-0005-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["5"],"URL":"https:\/\/doi.org\/10.1007\/s11897-004-0005-8","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}